tiprankstipranks
Else Nutrition Holdings (TSE:BABY)
TSX:BABY
Want to see TSE:BABY full AI Analyst Report?

Else Nutrition Holdings (BABY) AI Stock Analysis

85 Followers

Top Page

TSE:BABY

Else Nutrition Holdings

(TSX:BABY)

Select Model
Select Model
Select Model
Neutral 41 (OpenAI - 5.2)
Rating:41Neutral
Price Target:
C$0.03
▼(-72.50% Downside)
Action:Reiterated
Date:05/17/26
The score is primarily held down by weak financial performance (declining revenue, negative gross profit, large net losses, negative free cash flow, and negative equity). Technicals are slightly stabilizing near the 20-day average but remain bearish versus longer-term moving averages and a negative MACD. Valuation metrics provide little support due to a negative P/E and no dividend yield.
Positive Factors
Focused plant-based nutrition niche
A focused product set targeting plant-based toddler and child nutrition creates durable differentiation versus commodity formula makers. Structural consumer shifts toward plant-based diets and specialized allergy-friendly formulas support longer-term addressable market growth and pricing/brand premium opportunities.
Negative Factors
Declining revenue and negative gross margin
A falling top line combined with a negative gross margin undermines the fundamental ability to scale profitably. Persistent negative unit economics mean growth amplifies losses unless cost of goods or pricing structure is meaningfully improved, creating a sustained barrier to durable profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
Focused plant-based nutrition niche
A focused product set targeting plant-based toddler and child nutrition creates durable differentiation versus commodity formula makers. Structural consumer shifts toward plant-based diets and specialized allergy-friendly formulas support longer-term addressable market growth and pricing/brand premium opportunities.
Read all positive factors

Else Nutrition Holdings (BABY) vs. iShares MSCI Canada ETF (EWC)

Else Nutrition Holdings Business Overview & Revenue Model

Company Description
Else Nutrition Holdings Inc. engages in the development, production, and sale of food and nutrition products for infants, toddlers, children, and adults in North America and Israel. It offers baby snacks; baby feeding accessories, such as feeding ...
How the Company Makes Money
Else Nutrition makes money primarily by selling branded plant-based nutrition products. Its core revenue stream is product sales of Else-branded nutritional formulations (notably toddler nutrition products) to end consumers and to retail and distr...

Else Nutrition Holdings Earnings Call Summary

Earnings Call Date:Sep 16, 2025
(Q2-2025)
|
% Change Since: |
Next Earnings Date:Aug 17, 2026
Earnings Call Sentiment Neutral
Else Nutrition has shown significant progress in reducing costs and improving operational efficiency, with promising advancements in regulatory pathways and international growth. However, challenges such as revenue decline, negative gross margin, and inventory constraints have impacted performance.
Positive Updates
Expansion of Kids Ready-to-Drink Products
Else Nutrition's kids ready-to-drink products expanded to approximately 1,000 Walmart stores, showing significant market penetration and consumer interest.
Negative Updates
Revenue Decline
Total revenues for Q2 2025 were $1.5 million compared to $2.6 million in Q2 2024, mainly due to inventory constraints.
Read all updates
Q2-2025 Updates
Negative
Expansion of Kids Ready-to-Drink Products
Else Nutrition's kids ready-to-drink products expanded to approximately 1,000 Walmart stores, showing significant market penetration and consumer interest.
Read all positive updates
Company Guidance
During Else Nutrition's 2025 Second Quarter Conference Call, CEO Hamutal Yitzhak outlined several key metrics and strategic initiatives demonstrating the company's progress. The quarter saw total revenues of $1.5 million, a decrease from $2.6 million in Q2 2024, primarily due to inventory constraints and seasonal sales fluctuations. Gross profit faced a loss of $55,000, translating to a negative gross margin of -3.7%, affected by additional revenue reductions of CAD 270,000. Despite these challenges, operating expenses were significantly reduced by 60% year-over-year to $1.3 million, leading to a narrowed operating loss of $1.4 million, an improvement of 55% from the previous year. Else is targeting cash flow positivity by late 2026 or early 2027, focusing on supply chain optimization, regulatory advancements, and strategic partnerships to enhance growth and profitability.

Else Nutrition Holdings Financial Statement Overview

Summary
Weak fundamentals: TTM revenue declined (~-10%), gross profit is negative (about -29% gross margin), and the company remains deeply loss-making (~-108% net margin). Balance-sheet risk is elevated with negative stockholders’ equity, and liquidity pressure persists as TTM operating cash flow and free cash flow are both negative (~-$2.7M), implying ongoing funding dependence despite some improvement versus earlier years.
Income Statement
12
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
14
Very Negative
BreakdownMar 2026Mar 2025Dec 2023Mar 2023Mar 2022
Income Statement
Total Revenue6.03M7.97M9.36M8.53M4.69M
Gross Profit-2.61M-5.64M-85.00K1.31M743.00K
EBITDA-6.05M-14.78M-15.17M-17.12M-1.23M
Net Income-8.88M-15.18M-15.61M-17.61M-1.62M
Balance Sheet
Total Assets3.12M7.56M16.07M26.16M32.92M
Cash, Cash Equivalents and Short-Term Investments171.00K103.00K4.92M15.38M24.28M
Total Debt1.86M874.00K5.53M3.37M941.00K
Total Liabilities7.20M5.80M9.35M10.57M6.15M
Stockholders Equity-4.08M1.75M6.72M15.60M26.77M
Cash Flow
Free Cash Flow-3.18M-9.12M-18.31M-21.07M-16.05M
Operating Cash Flow-3.18M-9.06M-18.31M-20.91M-15.76M
Investing Cash Flow42.00K2.71M-1.13M170.00K1.14M
Financing Cash Flow2.89M3.73M7.44M11.69M16.85M

Else Nutrition Holdings Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.12
Price Trends
50DMA
0.05
Negative
100DMA
0.07
Negative
200DMA
0.12
Negative
Market Momentum
MACD
>-0.01
Negative
RSI
42.55
Neutral
STOCH
46.67
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:BABY, the sentiment is Negative. The current price of 0.12 is above the 20-day moving average (MA) of 0.04, above the 50-day MA of 0.05, and below the 200-day MA of 0.12, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 42.55 is Neutral, neither overbought nor oversold. The STOCH value of 46.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:BABY.

Else Nutrition Holdings Peers Comparison

Overall Rating
UnderperformOutperform
Sector (62)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
62
Neutral
$20.33B14.63-3.31%3.23%1.93%-12.26%
62
Neutral
C$1.43B40.4015.25%2.67%12.52%37.38%
57
Neutral
C$59.52M33.3847.73%75.19%44.09%
48
Neutral
C$25.77M-1.45-1208.82%337.52%-8.78%
44
Neutral
C$181.76M-11.48-92.94%119.70%-368.06%
41
Neutral
C$1.68M-1.095435.74%-31.80%76.06%
* Consumer Defensive Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
TSE:BABY
Else Nutrition Holdings
0.03
-0.07
-69.70%
TSE:BU
Burcon Nutrascience
2.00
0.00
0.00%
TSE:JWEL
Jamieson Wellness Inc
35.11
0.71
2.06%
TSE:HBFG
Happy Belly Food Group
1.40
0.35
33.33%
TSE:NPRA
Nepra Foods
0.48
0.35
255.56%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: May 17, 2026